Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm phase 4 study of sunitinib in advanced unresectable pancreatic neuroendocrine tumors
NL-OMON37660Phase 4Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sunitinib in islet cell tumor, sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jun 2012; status: active, not recruiting.
02
Drugs
sunitinib
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on NL-OMON37660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37660.